<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2018-06-05" updated="2020-01-02">
  <drugbank-id primary="true">DB14048</drugbank-id>
  <name>Sodium zirconium cyclosilicate</name>
  <description>Sodium zirconium cyclosilicate is approved as the trade product Lokelma developed by AstraZeneca - an insoluble, non-absorbed sodium zirconium silicate, formulated as a powder for oral suspension that acts as a highly selective potassium removing agent [L2933]. It is administered orally, is odorless, tasteless, and stable at room temperature [L2933]. It is a new medication that offers rapid and sustained treatment for adults with hyperkalaemia [L2933]. Approvals of the medication is supported by data from three double-blind, placebo controlled trials and two open-label trials which show that for patients receiving Lokelma the onset of action was at 1.0 hour and the median time to achieving normal potassium levels in the blood was 2.2 hours, with 92% of patients achieving normal potassium levels within 48 hours from baseline [L2933]. The treatment effect was maintained for up to 12 months [L2933].</description>
  <cas-number>17141-74-1</cas-number>
  <unii>D652ZWF066</unii>
  <average-mass>365.452</average-mass>
  <monoisotopic-mass>363.77144</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>approved</group>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles/>
    <textbooks/>
    <links>
      <link>
        <ref-id>L2930</ref-id>
        <title>AstraZeneca: ZS-9 (sodium zirconium cyclosilicate) Phase III long-term safety and efficacy data presented at ASN Kidney Week 2017</title>
        <url>https://www.astrazeneca.com/media-centre/medical-releases/zs-9-sodium-zirconium-cyclosilicate-phase-iii-long-term-safety-and-efficacy-data-presented-at-asn-kidney-week-201702112017.html</url>
      </link>
      <link>
        <ref-id>L2933</ref-id>
        <title>AstraZeneca: Lokelma approved in the US for the treatment of adults with hyperkalaemia</title>
        <url>https://www.astrazeneca.com/media-centre/press-releases/2018/lokelma-approved-in-the-us-for-the-treatment-of-adults-with-hyperkalaemia-21052018.html</url>
      </link>
    </links>
    <attachments>
      <attachment>
        <ref-id>F130</ref-id>
        <title>EMA Sodium Zirconium Cyclosilicate Monograph</title>
        <url>//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/000/130/original/WC500246774.pdf?1528233036</url>
      </attachment>
    </attachments>
  </general-references>
  <synthesis-reference/>
  <indication>Sodium zirconium cyclosilicate is a potassium binder indicated for the treatment of hyperkalemia in adult patients [FDA Label, F130].</indication>
  <pharmacodynamics>Sodium zirconium cyclosilicate is capable of reducing serum potassium concentrations as quickly as one hour after ingestion and normokalaemia can be achieved typically within 24 to 48 hours [FDA Label, F130]. Sodium zirconium cyclosilicate does not affect serum calcium or magnesium concentrations, or urinary sodium excretion [FDA Label, F130]. A close correlation is observed between starting serum potassium levels and effect size; patients with higher starting serum potassium levels have greater reductions in serum potassium [FDA Label, F130]. As a consequence of the resultant reduction in serum potassium concentration, there is a reduction in urinary potassium excretion as well [FDA Label, F130]. In a study of healthy subjects given sodium zirconium cyclosilicate 5 or 10 grams daily for four days, a dose-dependent reduction in serum potassium concentration and total urinary potassium excretion were accompanied by mean increases in faecal potassium excretion [FDA Label, F130]. No statistically significant changes in urinary sodium excretion were observed [FDA Label, F130].&#13;
&#13;
Sodium zirconium cyclosilicate has also been observed to bind ammonium in vitro and in vivo, thereby removing ammonium and increasing serum bicarbonate levels [F130]. Patients treated with sodium zirconium cyclosilicate were documented as experiencing an increase of 1.1 mmol/L at 5 g once daily, 2.3 mmol/L at 10 g once daily, and 2.6 mmol/L at 15 g once daily in bicarbonate compared with a mean increase of 0.6 mmol/L for the patients receiving placebo [F130]. In an environment where other factors affecting renin and aldosterone were not controlled, sodium zirconium cyclosilicate demonstrated a dose-independent reduction in mean serum aldosterone levels (range of -30% to -31%) compared with the placebo group (+14%) [F130]. No consistent effect on systolic and diastolic blood pressure has yet to be observed [F130].&#13;
&#13;
Moreover, mean reductions in blood urea nitrogen (BUN) were observed in the 5 g (-1.1 mg/dL) and 10 g (-2.0 mg/dL) three times daily groups compared with small mean increases in the placebo (0.8 mg/dL) and low dose sodium zirconium cyclosilicate (0.3 mg/dL) [F130].</pharmacodynamics>
  <mechanism-of-action>Hyperkalemia is a condition defined by elevated potassium levels in the blood, often caused by cardiovascular, renal, and metabolic diseases [L2930]. Hyperkalemia occurs in 23 to 47% of patients with chronic kidney disease and/or chronic heart failure, and may lead to cardiac arrest and death [L2930].&#13;
&#13;
Sodium zirconium cyclosilicate is subsequently a non-absorbed, non-polymer inorganic powder with a uniform micropore structure that preferentially captures potassium in exchange for hydrogen and sodium cations [FDA Label, F130]. Sodium zirconium cyclosilicate is highly selective for potassium ions, even in the presence of other cations such as calcium and magnesium, in vitro [FDA Label, F130]. Sodium zirconium cyclosilicate captures potassium throughout the entire gastrointestinal (GI) tract and reduces the concentration of free potassium in the GI lumen, thereby lowering serum potassium levels and increasing fecal potassium excretion to resolve hyperkalemia [FDA Label, F130].</mechanism-of-action>
  <toxicity>Overdose with sodium zirconium cyclosilicate could lead to hypokalaemia [FDA Label, F130].</toxicity>
  <metabolism>Sodium zirconium cyclosilicate is an inorganic, insoluble compound that is not susceptible to enzymatic metabolism [F130]. Additionally, studies have shown it not to be systemically absorbed either [F130]. An in vivo mass balance study in rats showed that sodium zirconium cyclosilicate was recovered in the feces with no evidence of systemic absorption [F130]. Due to these factors and its insolubility, no in vivo or in vitro studies have thus far been performed to examine its effect on cytochrome P450 (CYP450) enzymes or transporter activity [F130].</metabolism>
  <absorption>Sodium zirconium cyclosilicate is an inorganic, insoluble compound that is not susceptible to enzymatic metabolism [F130]. Additionally, studies have shown it not to be systemically absorbed either [F130]. An in vivo mass balance study in rats showed that sodium zirconium cyclosilicate was recovered in the feces with no evidence of systemic absorption [F130]. Due to these factors and its insolubility, no in vivo or in vitro studies have thus far been performed to examine its effect on cytochrome P450 (CYP450) enzymes or transporter activity [F130].</absorption>
  <half-life>Sodium zirconium cyclosilicate is an inorganic, insoluble compound that is not susceptible to enzymatic metabolism [F130]. Additionally, studies have shown it not to be systemically absorbed either [F130]. An in vivo mass balance study in rats showed that sodium zirconium cyclosilicate was recovered in the feces with no evidence of systemic absorption [F130]. Due to these factors and its insolubility, no in vivo or in vitro studies have thus far been performed to examine its effect on cytochrome P450 (CYP450) enzymes or transporter activity [F130].</half-life>
  <protein-binding>Sodium zirconium cyclosilicate is an inorganic, insoluble compound that is not susceptible to enzymatic metabolism [F130]. Additionally, studies have shown it not to be systemically absorbed either [F130]. An in vivo mass balance study in rats showed that sodium zirconium cyclosilicate was recovered in the feces with no evidence of systemic absorption [F130]. Due to these factors and its insolubility, no in vivo or in vitro studies have thus far been performed to examine its effect on cytochrome P450 (CYP450) enzymes or transporter activity [F130].</protein-binding>
  <route-of-elimination>Sodium zirconium cyclosilicate is eliminated via the feces [F130].</route-of-elimination>
  <volume-of-distribution>Sodium zirconium cyclosilicate is an inorganic, insoluble compound that is not susceptible to enzymatic metabolism [F130]. Additionally, studies have shown it not to be systemically absorbed either [F130]. An in vivo mass balance study in rats showed that sodium zirconium cyclosilicate was recovered in the feces with no evidence of systemic absorption [F130]. Due to these factors and its insolubility, no in vivo or in vitro studies have thus far been performed to examine its effect on cytochrome P450 (CYP450) enzymes or transporter activity [F130].</volume-of-distribution>
  <clearance>Sodium zirconium cyclosilicate is an inorganic, insoluble compound that is not susceptible to enzymatic metabolism [F130]. Additionally, studies have shown it not to be systemically absorbed either [F130]. An in vivo mass balance study in rats showed that sodium zirconium cyclosilicate was recovered in the feces with no evidence of systemic absorption [F130]. Due to these factors and its insolubility, no in vivo or in vitro studies have thus far been performed to examine its effect on cytochrome P450 (CYP450) enzymes or transporter activity [F130].</clearance>
  <salts/>
  <synonyms>
    <synonym language="english" coder="usan">Sodium zirconium cyclosilicate</synonym>
    <synonym language="english" coder="">Sodium zirconium silicate</synonym>
  </synonyms>
  <products>
    <product>
      <name>Lokelma</name>
      <labeller>Astra Zeneca</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02490714</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-10-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for suspension</dosage-form>
      <strength>5 g</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Lokelma</name>
      <labeller>Astra Zeneca</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02490722</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-10-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for suspension</dosage-form>
      <strength>10 g</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Lokelma</name>
      <labeller>AstraZeneca Pharmaceuticals LP</labeller>
      <ndc-id/>
      <ndc-product-code>0310-1105</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-09-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for suspension</dosage-form>
      <strength>5 g/5g</strength>
      <route>Oral</route>
      <fda-application-number>NDA207078</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lokelma</name>
      <labeller>AstraZeneca Pharmaceuticals LP</labeller>
      <ndc-id/>
      <ndc-product-code>0310-1110</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-09-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for suspension</dosage-form>
      <strength>10 g/10g</strength>
      <route>Oral</route>
      <fda-application-number>NDA207078</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Lokelma</name>
      <ingredients>Sodium zirconium cyclosilicate</ingredients>
    </mixture>
    <mixture>
      <name>Lokelma</name>
      <ingredients>Sodium zirconium cyclosilicate</ingredients>
    </mixture>
    <mixture>
      <name>Lokelma</name>
      <ingredients>Sodium zirconium cyclosilicate</ingredients>
    </mixture>
    <mixture>
      <name>Lokelma</name>
      <ingredients>Sodium zirconium cyclosilicate</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Acids</category>
      <mesh-id>D000143</mesh-id>
    </category>
    <category>
      <category>Acids, Noncarboxylic</category>
      <mesh-id>D000148</mesh-id>
    </category>
    <category>
      <category>Anions</category>
      <mesh-id>D000838</mesh-id>
    </category>
    <category>
      <category>Drugs for Treatment of Hyperkalemia and Hyperphosphatemia</category>
      <mesh-id/>
    </category>
    <category>
      <category>Electrolytes</category>
      <mesh-id>D004573</mesh-id>
    </category>
    <category>
      <category>Ions</category>
      <mesh-id>D007477</mesh-id>
    </category>
    <category>
      <category>Minerals</category>
      <mesh-id>D008903</mesh-id>
    </category>
    <category>
      <category>Oxides</category>
      <mesh-id>D010087</mesh-id>
    </category>
    <category>
      <category>Oxygen Compounds</category>
      <mesh-id>D017601</mesh-id>
    </category>
    <category>
      <category>Potassium-removing Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Silicon Compounds</category>
      <mesh-id>D017655</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Powder, for suspension</form>
      <route>Oral</route>
      <strength>10 g</strength>
    </dosage>
    <dosage>
      <form>Powder, for suspension</form>
      <route>Oral</route>
      <strength>10 g/10g</strength>
    </dosage>
    <dosage>
      <form>Powder, for suspension</form>
      <route>Oral</route>
      <strength>5 g</strength>
    </dosage>
    <dosage>
      <form>Powder, for suspension</form>
      <route>Oral</route>
      <strength>5 g/5g</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="V03AE10">
      <level code="V03AE">Drugs for treatment of hyperkalemia and hyperphosphatemia</level>
      <level code="V03A">ALL OTHER THERAPEUTIC PRODUCTS</level>
      <level code="V03">ALL OTHER THERAPEUTIC PRODUCTS</level>
      <level code="V">VARIOUS</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>40:18.18</ahfs-code>
  </ahfs-codes>
  <pdb-entries/>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB14048.pdf?1528233045</fda-label>
  <patents>
    <patent>
      <number>9592253</number>
      <country>United States</country>
      <approved>2017-03-14</approved>
      <expires>2035-10-14</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8808750</number>
      <country>United States</country>
      <approved>2014-08-19</approved>
      <expires>2032-02-10</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9844567</number>
      <country>United States</country>
      <approved>2017-12-19</approved>
      <expires>2032-02-10</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9861658</number>
      <country>United States</country>
      <approved>2018-01-09</approved>
      <expires>2032-02-10</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>6332985</number>
      <country>United States</country>
      <approved>2001-12-25</approved>
      <expires>2019-03-29</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8877255</number>
      <country>United States</country>
      <approved>2014-11-04</approved>
      <expires>2033-10-22</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8802152</number>
      <country>United States</country>
      <approved>2014-08-12</approved>
      <expires>2032-04-19</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9913860</number>
      <country>United States</country>
      <approved>2018-03-13</approved>
      <expires>2033-10-22</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>10335432</number>
      <country>United States</country>
      <approved>2019-07-02</approved>
      <expires>2032-02-10</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>10300087</number>
      <country>United States</country>
      <approved>2019-05-28</approved>
      <expires>2035-10-14</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions/>
  <drug-interactions/>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>-3.8</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>disodium 1,3,5,2,4,6-trioxatrisilinane-2,2,4,4,6,6-hexakis(olate) zirconium</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>topramezone</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>365.452</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>363.77144</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>[Na+].[Na+].[Zr].[O-][Si]1([O-])O[Si]([O-])([O-])O[Si]([O-])([O-])O1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>Na2O9Si3Zr</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/2Na.O9Si3.Zr/c;;1-10(2)7-11(3,4)9-12(5,6)8-10;/q2*+1;-6;</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>ARVUQMBOTBOHPL-UHFFFAOYSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>166.05</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>12.71</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>12.77</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>9</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>6.97</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>-4.4</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>-1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties/>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>23336</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D10727</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Sodium_zirconium_cyclosilicate</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets/>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>